Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

2.43USD
20 Sep 2017
Change (% chg)

$0.01 (+0.41%)
Prev Close
$2.42
Open
$2.40
Day's High
$2.46
Day's Low
$2.40
Volume
303,259
Avg. Vol
884,064
52-wk High
$3.20
52-wk Low
$0.94

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.62
Market Cap(Mil.): $204.62
Shares Outstanding(Mil.): 84.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

* Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

Aug 30 2017

BRIEF-Catalyst Pharmaceuticals Q2 GAAP loss per share $0.05

* Catalyst pharmaceuticals announces second quarter 2017 financial results and provides corporate update

Aug 09 2017

BRIEF-Catalyst Pharmaceuticals files for mixed shelf of up to $150 mln

* Catalyst Pharmaceuticals Inc files for mixed shelf of up to $150 million - SEC filing Source text for Eikon: (http://bit.ly/2tflLhO) Further company coverage:

Jul 12 2017

Competitors

Earnings vs. Estimates